16 September 2026 editorial review · Trial
AI bolus priming added to AIDANET: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Baseline trial evidence review: A–H
Outcome: Expanded sparse summary/eligibility using current registry design, inclusion criteria and primary outcome; no efficacy inferred from registration.
Registry: NCT07517770. Registered endpoint checked: Time in Range (TIR) 70-180 mg/dL for 2-week free-living at home periods on AIDANET vs AIDANET AI. (two weeks). Eligibility check: Registry age 18 Years to not specified; substantive diagnosis/stage, device and other inclusion restrictions were compared with the public eligibility summary. The registry remains the source for full exclusions. Limits: No usable primary abstract was independently recovered in this pass for this record. Protocol/design wording was assessed; any existing detailed sponsor, conference or historical outcome claims require their cited source and were not independently certified through full-text review.